What this means
This is a trial that has not yet reported results. It plans to test whether a weight-loss drug might affect markers of aging in 90 adults.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 55–70 · 90 adults aged 55 to 70
- Where
- 1 site, including Texas
The science
- Registered title
- Tirzepatide to Slow Biological Aging
- Trial ID
- NCT07220473 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Aging, LONGEVITY 1
- What is tested
- Zepbound
- Sponsor
- The University of Texas Medical Branch, Galveston
- Ages
- 55 Years to 70 Years
- Dates
- First posted Oct 24, 2025 · updated Mar 24, 2026
Registry summary
This pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg subcutaneously (SC) weekly or no drug for 24 weeks, followed by 12 weeks off the drug. Since tirzepatide is already recognized as a highly effective weight-loss agent in this population, the primary focus will not be on measuring weight loss. Instead, the study will document the effects of tirzepatide on markers of aging, physical function, and overall health.
Sites (1)
- University of Texas Medical Branch, Galveston, Texas, United States